alcestobart (LBL-007) / Leads Biolabs, BeOne Medicines - LARVOL DELTA

BGB-A317-LBL-007-202: A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma (clinicaltrials.gov) - P2 | N=118 | Active, not recruiting | Sponsor: BeiGene | Trial completion date: Sep 2025 ➔ May 2026

Trial completion date • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma

A novel fully human LAG-3 monoclonal antibody LBL-007 combined with PD-1 antibody inhibits proliferation, migration and invasion of tumor cells via blocking NF-κB pathway (PubMed, Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi) - "Treatment with the NF-κB signaling pathway agonist TNF-α reversed the suppressive effects of LBL-007 and BE0188 on tumor cell proliferation, invasion, migration, and NF-κB signaling. Conclusion LBL-007 and anti-PD-1 antibody synergistically inhibit the invasion, migration, and proliferation of A549 and MGC803 tumor cells by blocking the NF-κB signaling pathway."

IO biomarker • Journal • Oncology • LAG3 • MMP2 • MMP9 • NFKBIA • TNFA

Updated efficacy, safety and biomarker analysis of a phase 2 study of LBL-007 (alcestobart, an anti-LAG-3 mAb) combined with tislelizumab (an anti–PD-1 mAb) and chemotherapy in previously untreated recurrent or metastatic nasopharyngeal carcinoma (R/M NPC). (ASCO 2025) - P1/2, P3 | " Untreated R/M NPC patients received gemcitabine at 1 g/m² on days 1 and 8, cisplatin at 80 mg/m² on day 1 (GP) in combination with LBL-007 600 mg and tislelizumab 200 mg on day 1 of every 3 weeks, the chemotherapy was up to 6 cycles, followed by LBL-007 and tislelizumab on day 1 of every 3 weeks as maintenance therapy. LBL-007/tislelizumab combined with GP chemotherapy has shown encouraging ORR, PFS and DoR in R/M NPC as first-line treatment with favorable safety profiles. These findings support a pivotal phase III study comparing LBL-007/tislelizumab plus GP with tislelizumab plus GP in R/M NPC in 1L setting. The correlation between higher LAG-3 expression and improved efficacy was observed, which warranted further validation in larger population."

Biomarker • Clinical • IO biomarker • Metastases • P2 data • Nasopharyngeal Carcinoma • Oncology • Solid Tumor • LAG3

Liberty-201: A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer (clinicaltrials.gov) - P1/2 | N=113 | Active, not recruiting | Sponsor: BeiGene | Trial completion date: Apr 2026 ➔ Dec 2026 | Trial primary completion date: Apr 2026 ➔ May 2025

Mismatch repair • pMMR • Trial completion date • Trial primary completion date • Colorectal Cancer • Oncology • Solid Tumor • PD-L1

BGB-LC-201: A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer (clinicaltrials.gov) - P2 | N=400 | Active, not recruiting | Sponsor: BeiGene | Trial completion date: Jul 2025 ➔ Oct 2025 | Trial primary completion date: Jul 2025 ➔ Oct 2025

Trial completion date • Trial primary completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

BGB-A317-290-LTE1: Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies (clinicaltrials.gov) - P3 | N=430 | Enrolling by invitation | Sponsor: BeiGene | N=300 ➔ 430

Enrollment change • Oncology • Solid Tumor

2025 ASCO: Encouraging Clinical Data from Leads Biolabs' Innovative Bispecific Antibody LBL-024 against PD-L1 and 4-1BB Selected for Oral Presentation (Leads Biolabs Press Release) - "Nanjing Leads Biolabs Co., Ltd...announced that two of its innovative oncology assets, LBL-024 and LBL-007, have been selected for oral and poster presentations, respectively, at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held in Chicago from May 30 to June 3. The selection highlights the strong clinical potential and innovation of Leads Biolabs’ immuno-oncology pipeline."

Clinical data • Nasopharyngeal Carcinoma • Neuroendocrine Tumor

BGB-LC-202: Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer (clinicaltrials.gov) - P2 | N=121 | Completed | Sponsor: BeiGene | Active, not recruiting ➔ Completed | Trial completion date: Dec 2026 ➔ Jan 2025 | Trial primary completion date: Dec 2026 ➔ Jan 2025

Monotherapy • Trial completion • Trial completion date • Trial primary completion date • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

Anti-LAG-3 antibody LBL-007 plus anti-PD-1 antibody toripalimab in advanced nasopharyngeal carcinoma and other solid tumors: an open-label, multicenter, phase Ib/II trial. (PubMed, J Hematol Oncol) - "LBL-007 plus toripalimab exhibited a manageable safety profile in patients with advanced solid tumors and demonstrated promising antitumor activity in NPC, especially in immunotherapy-naive patients. These findings warrant further validation in future studies."

IO biomarker • Journal • P1/2 data • Cardiovascular • Fatigue • Heart Failure • Hematological Disorders • Nasopharyngeal Carcinoma • Oncology • Solid Tumor • PD-L1

BGB-900-102: Study of BGB-A425 and LBL-007 in Combination With Tislelizumab in Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=114 | Completed | Sponsor: BeiGene | Active, not recruiting ➔ Completed

Trial completion • Head and Neck Cancer • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • PD-L1

BGB-LC-201: A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer (clinicaltrials.gov) - P2 | N=400 | Active, not recruiting | Sponsor: BeiGene | Recruiting ➔ Active, not recruiting

Enrollment closed • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma (clinicaltrials.gov) - P1 | N=88 | Recruiting | Sponsor: Nanjing Leads Biolabs Co.,Ltd | Trial completion date: Jun 2025 ➔ Dec 2025 | Trial primary completion date: Mar 2025 ➔ Jul 2025

Trial completion date • Trial primary completion date • Melanoma • Oncology • Solid Tumor

BGB-900-102: Study of BGB-A425 and LBL-007 in Combination With Tislelizumab in Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=114 | Active, not recruiting | Sponsor: BeiGene | Recruiting ➔ Active, not recruiting | N=358 ➔ 114

Enrollment change • Enrollment closed • Head and Neck Cancer • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • PD-L1

Liberty-201: A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer (clinicaltrials.gov) - P1/2 | N=113 | Active, not recruiting | Sponsor: BeiGene | Recruiting ➔ Active, not recruiting | N=226 ➔ 113 | Trial completion date: Apr 2028 ➔ Apr 2026 | Trial primary completion date: Apr 2028 ➔ Apr 2026

Enrollment change • Enrollment closed • Mismatch repair • Trial completion date • Trial primary completion date • Colorectal Adenocarcinoma • Colorectal Cancer • Oncology • Solid Tumor • PD-L1

Phase Ib/II Clinical Study of LBL-007 in Treatment of Advanced Malignant Tumors (clinicaltrials.gov) - P1/2 | N=200 | Recruiting | Sponsor: Nanjing Leads Biolabs Co.,Ltd | Trial completion date: Mar 2025 ➔ Aug 2025 | Trial primary completion date: Dec 2024 ➔ Jun 2025

Trial completion date • Trial primary completion date • Oncology • Solid Tumor

BGB-HNSCC-201: Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - P2 | N=160 | Active, not recruiting | Sponsor: BeiGene | Recruiting ➔ Active, not recruiting

Combination therapy • Enrollment closed • Metastases • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • PD-L1

BGB-LC-202: Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer (clinicaltrials.gov) - P2 | N=121 | Active, not recruiting | Sponsor: BeiGene | Recruiting ➔ Active, not recruiting

Enrollment closed • Monotherapy • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

LBL-007-CN-004: A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors (clinicaltrials.gov) - P1/2 | N=490 | Recruiting | Sponsor: Nanjing Leads Biolabs Co.,Ltd | Trial completion date: Jun 2025 ➔ Dec 2025 | Trial primary completion date: Oct 2024 ➔ Oct 2025

Combination therapy • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

Phase Ib/II study of the anti-LAG-3 antibody LBL-007 combined with the anti-PD-1 antibody tislelizumab ± chemotherapy in patients with advanced nasopharyngeal carcinoma and other malignancies (CSCO 2024) - "Study group: [Organizing Committee]"

Clinical • Metastases • P1/2 data • Nasopharyngeal Carcinoma • Oncology • Solid Tumor

BGB-900-102: Study of BGB-A425 and LBL-007 in Combination with Tislelizumab in Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=358 | Recruiting | Sponsor: BeiGene | Trial completion date: Dec 2027 ➔ Apr 2025 | Trial primary completion date: Mar 2026 ➔ Apr 2025

Trial completion date • Trial primary completion date • Head and Neck Cancer • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • PD-L1

Two studies were presented at the CSCO conference! Weilizhibo's innovative drug clinical research has made another major achievement [Google translation] (bydrug.pharmcube.com) - P1b/2 | N=490 | NCT05516914 | Sponsor: Nanjing Leads Biolabs Co.,Ltd | "The LBL-007 Phase Ib/II clinical study (NCT05516914) was led by Professor Zhang Li from the Cancer Center of Sun Yat-sen University and conducted in 10 centers across the country. It aims to evaluate the safety and efficacy of LBL-007 combined with anti-PD-1 antibody tislelizumab ± chemotherapy in the treatment of advanced solid tumors (Phase Ib study) and advanced nasopharyngeal carcinoma patients who have not received previous treatment (Phase II study). The research data released this time showed....Phase II included 42 patients with previously untreated recurrent or metastatic nasopharyngeal carcinoma, who received LBL-007 combined with tislelizumab and GC chemotherapy. Among the 41 patients with evaluable efficacy, the ORR was 90.2%, the disease control rate (DCR) was 100%, and the 3-month progression-free survival rate was 97.6%."

P1/2 data • Nasopharyngeal Carcinoma • Solid Tumor

A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma (clinicaltrials.gov) - P1 | N=88 | Recruiting | Sponsor: Nanjing Leads Biolabs Co.,Ltd | Trial completion date: Dec 2024 ➔ Jun 2025 | Trial primary completion date: Aug 2024 ➔ Mar 2025

Trial completion date • Trial primary completion date • Melanoma • Oncology • Solid Tumor

Phase Ib/II Clinical Study of LBL-007 in Treatment of Advanced Malignant Tumors (clinicaltrials.gov) - P1/2 | N=200 | Recruiting | Sponsor: Nanjing Leads Biolabs Co.,Ltd | Trial completion date: Dec 2024 ➔ Mar 2025 | Trial primary completion date: Jul 2024 ➔ Dec 2024

Combination therapy • Metastases • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

BeiGene Enters Next Phase of Global Growth with Announcement of Second Quarter 2024 Financial Results and Corporate Updates (Businesswire) - "BGB-16673 (BTK CDAC): Anticipating first subject enrolled in Phase 3 program in fourth quarter of 2024 or first quarter of 2025....Multiple randomized tislelizumab lung cancer combination cohorts with BGB-A445 (anti-OX40), LBL-007 (anti-LAG3) and BGB-15025 (HPK1 inhibitor) expected to read out in 2024....Pan-KRAS, MTA-cooperative PRMT5 inhibitors and EGFR CDAC targeted protein degrader on track to enter the clinic in the second half of 2024."

Clinical data • New P3 trial • New trial • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology

BGB-A317-290-LTE1: Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies (clinicaltrials.gov) - P3 | N=300 | Enrolling by invitation | Sponsor: BeiGene | Trial completion date: Aug 2024 ➔ Dec 2026 | Trial primary completion date: Aug 2024 ➔ Dec 2026

Metastases • Trial completion date • Trial primary completion date • Oncology • Solid Tumor